Soledad Ojeda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Soledad Ojeda has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Dolores Mesa
Servicio de Cardiología, Hospital Universitario Reina Sofía, Córdoba, Spain
3 shared publicationsFederico Vallés
Department of Cardiology, Hospital Universitario Reina Sofía , Córdoba
3 shared publicationsManuel Anguita
Department of Cardiology, Hospital Universitario Reina Sofía , Córdoba
3 shared publicationsMónica Delgado
Servicio de Cardiología, Hospital Universitario Reina Sofía, Córdoba, Spain
3 shared publicationsCarmen Rus
Department of Cardiology, Hospital Universitario Reina Sofía , Córdoba
2 shared publicationsDjordje Pavlovic
Servicio de Cardiología, Hospital Universitario Reina Sofía, Córdoba, Spain
2 shared publications
Latest Publications
- 1 June 2013
- Published by Elsevier in Revista Española de Cardiología (English Edition)
- Vol. 66 (6) , 450-457
Functional Improvement in Patients With Dilated Cardiomyopathy After the Intracoronary Infusion of Autologous Bone Marrow Mononuclear Cells
- 1 June 2013
- Published by Elsevier in Revista Española de Cardiología (English Edition)
- Vol. 66 (6) , 450-457
Functional Improvement in Patients With Dilated Cardiomyopathy After the Intracoronary Infusion of Autologous Bone Marrow Mononuclear Cells
- 1 August 2005
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 7 (5) , 921-926
Short- and Long-Term Results of a Programme for the Prevention of Readmissions and Mortality in Patients with Heart Failure: Are Effects Maintained After Stopping the Programme?
The objective of the study was to evaluate whether improvements obtained during an intervention programme were maintained after the programme was stopped. 153 patients discharged with a diagnosis of heart failure (HF) were randomized to either usual care or an intervention programme, which included patient education, consultation with the cardiologist and monitoring in the Heart Failure Unit. After an average period of 16±8 months, the intervention programme was stopped. One year later, all the patients were re-examined to assess HF readmissions, all-cause mortality, quality of life, and prescribed medical treatment. During the 16±8-month treatment period, patients in the intervention group had a lower rate of HF readmissions (17% vs. 51%, p<0.01), less all-cause mortality (13% vs. 27%, p=0.03), improvement in quality of life (1.5±0.8 vs. 1.9±1, p=0.03) and optimisation of medical treatment was achieved. One year after stopping the intervention, there was no difference in HF readmissions (28% vs. 25%, p=0.72), all-cause mortality (14% vs. 17%, p=0.64) and quality of life (1.7±0.9 vs. 1.8±1, p=0.24) between the groups. Survival and the probability of not being readmitted due to HF were similar in both groups. There was also a reduction in the use of beta-blockers and spironolactone in the intervention group. Conclusions: The positive effects of an intervention programme are clearly reduced when it is stopped, due to less strict control of the patients and a decrease in the use of drugs with proven efficacy in HF.
- 1 August 2005
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 7 (5) , 921-926
Short- and Long-Term Results of a Programme for the Prevention of Readmissions and Mortality in Patients with Heart Failure: Are Effects Maintained After Stopping the Programme?
The objective of the study was to evaluate whether improvements obtained during an intervention programme were maintained after the programme was stopped. 153 patients discharged with a diagnosis of heart failure (HF) were randomized to either usual care or an intervention programme, which included patient education, consultation with the cardiologist and monitoring in the Heart Failure Unit. After an average period of 16±8 months, the intervention programme was stopped. One year later, all the patients were re-examined to assess HF readmissions, all-cause mortality, quality of life, and prescribed medical treatment. During the 16±8-month treatment period, patients in the intervention group had a lower rate of HF readmissions (17% vs. 51%, p<0.01), less all-cause mortality (13% vs. 27%, p=0.03), improvement in quality of life (1.5±0.8 vs. 1.9±1, p=0.03) and optimisation of medical treatment was achieved. One year after stopping the intervention, there was no difference in HF readmissions (28% vs. 25%, p=0.72), all-cause mortality (14% vs. 17%, p=0.64) and quality of life (1.7±0.9 vs. 1.8±1, p=0.24) between the groups. Survival and the probability of not being readmitted due to HF were similar in both groups. There was also a reduction in the use of beta-blockers and spironolactone in the intervention group. Conclusions: The positive effects of an intervention programme are clearly reduced when it is stopped, due to less strict control of the patients and a decrease in the use of drugs with proven efficacy in HF.
- 1 November 2003
- Published by Elsevier in Revista Espanola de Cardiologia
- Vol. 56 (11) , 1050-1056
Características clínicas y pronóstico a medio plazo de la insuficiencia cardíaca con función sistólica conservada. ¿Es diferente de la insuficiencia cardíaca sistólica?
- 1 November 2003
- Published by Elsevier in Revista Espanola de Cardiologia
- Vol. 56 (11) , 1050-1056
Características clínicas y pronóstico a medio plazo de la insuficiencia cardíaca con función sistólica conservada. ¿Es diferente de la insuficiencia cardíaca sistólica?
- 1 May 2003
- Published by Elsevier in Revista Espanola de Cardiologia
- Vol. 56 (5) , 459-464
Recuperación tardía de la reserva coronaria en pacientes tratados con éxito mediante revascularización percutánea
- 1 May 2003
- Published by Elsevier in Revista Espanola de Cardiologia
- Vol. 56 (5) , 459-464
Recuperación tardía de la reserva coronaria en pacientes tratados con éxito mediante revascularización percutánea
- 1 January 2000
- Published by Elsevier in Revista Espanola de Cardiologia
- Vol. 53 (7) , 927-931
Insuficiencia cardíaca debida a disfunción ventricular sistólica severa de origen hipertensivo. Evolución clínica y funcional a largo plazo
- 1 January 2000
- Published by Elsevier in Revista Espanola de Cardiologia
- Vol. 53 (7) , 927-931
Insuficiencia cardíaca debida a disfunción ventricular sistólica severa de origen hipertensivo. Evolución clínica y funcional a largo plazo